fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study showed that APD421 significantly reduced the incidence of nausea and vomiting compared to placebo in adult surgical patients at moderate-to-high risk of suffering PONV. Vomiting and especially nausea remain a major problem...
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it contemplates restructuring the company’s operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-TacroT, Veloxis’ product candidate for the prevention of organ rejection. It is planned that a discontinuation of other pipeline activities will take place, including...
 MPM Capital and LSP Life Sciences Partners join existing Celladon investment syndicate – Total capital proceeds of recent investment round increased to $53 million San Diego, California, May 7, 2012/PRNewswire/ — Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced the receipt of additional capital proceeds...
  BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that it has been selected as a Top 100 Winner for Red Herring's 2012 Europe Award, a prestigious list honoring the year's most promising private technology ventures from the European business region....
  Lund, SWEDEN, BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic replacement surgeries, today announced the appointment of Andreas Muchowski to the position of Vice President of Sales Germany. Andreas will lead sales recruiting efforts and prepare for the upcoming market launch of exciting...
Sunnyvale, CA, Asante Solutions, Inc. (Asante), a medical device company focused on diabetes care, has strengthened its leadership team by adding David Thrower as president and chief executive officer, and Eric Steuben as vice president of operations. Former President and Chief Executive Officer Phil Hopper will remain as a special advisor and board member.  ...
LUND, Sweden, April 4, 2012 /PRNewswire/   BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgeries, today revealed details of a One Hundred Day Plan presented by Chief Executive Officer Lloyd Diamond. Mr. Diamond addresses key initiatives aimed at accelerating global commercialization of the...
BURLINGTON, MA (April 2, 2012): AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $25 million Series B venture financing. The round included the participation of new syndicate member Lundbeckfond Ventures, as well as previous investors SV Life Sciences and Novo A/S. AlloCure also...
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf® and has randomized over 540 patients at approximately 90 clinical sites around the world....
1 59 60 61 62 63 64

Lundbeckfonden Ventures

Nyheder

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
3. april 2020
Acacia Pharma Group PLC – Publication of Prospectus
25. marts 2020
Acacia Pharma Group PLC – Forthcoming 2020 Annual General Meeting – Change of Venue and Proxy Forms
23. marts 2020